Documentos relacionados

1. [Austrian expenditures on psychopharmaceutical drugs between 2006 and 2013].
2. The Affordable Care Act and access to care across the cancer control continuum: A review at 10 years.
3. Toward the single-hour high-quality genome.
4. Long-acting olanzapine versus long-acting risperidone for schizophrenia in Spain - a cost-effectiveness comparison.
5. Real-world data on new users of atypical antipsychotics: characterisation, prescription patterns, healthcare costs and early cardio-metabolic occurrences from a large Italian database.
6. Neighborhood Differences in Alternative Tobacco Product Availability and Advertising in New York City: Implications for Health Disparities.
7. Pharmaco-utilisation and related costs of drugs used to treat schizophrenia and bipolar disorder in Italy: the IBIS study.
8. Safety monitoring of treatment in bipolar disorder in a tertiary care setting in Sri Lanka and recommendations for improved monitoring in resource limited settings.
9. Regional Market Competition is Associated with Aneurysm Diameter at the Time of EVAR.
10. An Economic Evaluation of the All New Zealand Acute Coronary Syndrome Quality Improvement Registry Program (ANZACS-QI 28).